Teva Pharmaceutical Industries Ltd TEVA has reached a settlement worth $225 million to resolve claims the Company fueled an opioid epidemic in Texas.
- Texas Attorney General Ken Paxton said Teva agreed to pay $150 million over 15 years and provide $75 million worth of generic Narcan, a medication used to counter the effects of opioid overdoses.
- Teva did not admit wrongdoing as part of Monday's settlement.
- The Company will continue to defend itself in court in states where we have not reached a settlement agreement.
- A California judge in November concluded Teva and three other drugmakers could not be held responsible for causing the epidemic in several large counties in that state.
- Price Action: TEVA shares are up 0.65% at $8.57 during the market session on the last check Monday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in